Errol P Prens

List of Publications by Year
in descending order

148 papers	11,227 citations	46918 47 h-index	32761 100 g-index
150 all docs	150 docs citations	150 times ranked	8855 citing authors

#	Article	IF	Citations
1	Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial. Journal of the American Academy of Dermatology, 2022, 86, 854-862.	0.6	17
2	Clinical translation of hidradenitis suppurativa genetic studies requires global collaboration. British Journal of Dermatology, 2022, 186, 183-185.	1.4	7
3	Prevalence and Clinical Characteristics of Hidradenitis Suppurativa Phenotypes in a Large Dutch Cohort. Dermatology, 2022, 238, 600-602.	0.9	10
4	Insights into hidradenitis suppurativa. Journal of Allergy and Clinical Immunology, 2022, 149, 1150-1161.	1.5	28
5	Needleâ€free jet injectionâ€induced smallâ€droplet aerosol formation during intralesional bleomycin therapy. Lasers in Surgery and Medicine, 2022, 54, 572-579.	1.1	3
6	New insights in hidradenitis suppurativa from a populationâ€based Dutch cohort: prevalence, smoking behaviour, socioeconomic status and comorbidities*. British Journal of Dermatology, 2022, 186, 814-822.	1.4	19
7	Impact of hidradenitis suppurativa on work productivity and associated risk factors. Journal of the American Academy of Dermatology, 2021, 84, 1401-1405.	0.6	10
8	Noninvasive assessment of cytokine and antimicrobial peptide levels in hidradenitis suppurativa using transdermal analysis patches. British Journal of Dermatology, 2021, 184, 343-345.	1.4	4
9	Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders. Journal of the American Academy of Dermatology, 2021, 85, 258-260.	0.6	15
10	Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. Journal of Allergy and Clinical Immunology, 2021, 147, 857-869.e7.	1.5	45
11	Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study*. British Journal of Dermatology, 2021, 185, 177-184.	1.4	18
12	Target molecules for future hidradenitis suppurativa treatment. Experimental Dermatology, 2021, 30, 8-17.	1.4	34
13	Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa. Drugs, 2021, 81, 1397-1410.	4.9	26
14	No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis Suppurativa. Journal of Investigative Dermatology, 2021, 141, 2966-2969.e1.	0.3	7
15	Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa. JAMA Surgery, 2021, 156, 1001.	2.2	62
16	Interleukin-17A Drives IL-19 and IL-24 Expression in Skin Stromal Cells Regulating Keratinocyte Proliferation. Frontiers in Immunology, 2021, 12, 719562.	2.2	15
17	Current and future treatment of hidradenitis suppurativa. British Journal of Dermatology, 2020, 183, e178-e187.	1.4	23
18	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. Journal of the American Academy of Dermatology, 2020, 82, 117-122.	0.6	120

#	Article	IF	Citations
19	Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. Journal of the American Academy of Dermatology, 2020, 82, 366-376.	0.6	165
20	Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial. Dermatology and Therapy, 2020, 10, 1415-1421.	1.4	6
21	What causes hidradenitis suppurativa ?â€”15 years after. Experimental Dermatology, 2020, 29, 1154-1170.	1.4	90
22	Contribution of Genetics to the Susceptibility to Hidradenitis Suppurativa in a Large, Cross-sectional Dutch Twin Cohort. JAMA Dermatology, 2020, 156, 1359.	2.0	33
23	High and discordant prevalences of clinical and sonographic enthesitis in patients with hidradenitis suppurativa. British Journal of Dermatology, 2020, 183, 763-765.	1.4	3
24	Hidradenitis suppurativa. Nature Reviews Disease Primers, 2020, 6, 18.	18.1	286
25	Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients. Archives of Dermatological Research, 2020, 312, 715-724.	1.1	25
26	Low Prevalence of GSC Gene Mutations in a Large Cohort of Predominantly Caucasian Patients with Hidradenitis Suppurativa. Journal of Investigative Dermatology, 2020, 140, 2085-2088.e14.	0.3	47
27	Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice. American Journal of Clinical Dermatology, 2020, 21, 579-590.	3.3	16
28	A novel nicastrin mutation in a threeâ€generation Dutch family with hidradenitis suppurativa: a search for functional significance. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2353-2361.	1.3	16
29	Lesional Inflammatory Profile in Hidradenitis Suppurativa Is Not Solely Driven by IL-1. Journal of Investigative Dermatology, 2020, 140, 1463-1466.e2.	0.3	13
30	Omiganan Enhances Imiquimodâ€Induced Inflammatory Responses in Skin of Healthy Volunteers. Clinical and Translational Science, 2020, 13, 573-579.	1.5	15
31	Efficacy and tolerability of intralesional bleomycin in dermatology: A systematic review. Journal of the American Academy of Dermatology, 2020, 83, 888-903.	0.6	40
32	Physician severity scores correlate poorly with healthâ€related quality of life in patients with Hidradenitis Suppurativa. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e722-e724.	1.3	3
33	Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placeboâ€Controlled, Phase II Trial. Clinical and Translational Science, 2020, 13, 994-1003.	1.5	24
34	Interleukinâ€17A Is Produced by CD4+ but Not CD8+ T Cells in Synovial Fluid Following T Cell Receptor Activation and Regulates Different Inflammatory Mediators Compared to Tumor Necrosis Factor in a Model of Psoriatic Arthritis Synovitis. Arthritis and Rheumatology, 2020, 72, 1303-1313.	2.9	14
35	Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis. JCI Insight, 2020, 5, .	2.3	105
36	Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. Journal of the American Academy of Dermatology, 2019, 80, 60-69.e2.	0.6	126

#	Article	IF	Citations
37	Biofilm production and antibiotic susceptibility of Staphylococcus epidermidis strains from Hidradenitis Suppurativa lesions. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 170-177.	1.3	25
38	Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies. British Journal of Dermatology, 2019, 181, 1339-1341.	1.4	28
39	Apocrine Glandâ€“Rich Skin Has a Non-InflammatoryÂIL-17â€“Related Immune Milieu, thatÂTurns to Inflammatory IL-17â€“Mediated DiseaseÂin Hidradenitis Suppurativa. Journal of Investigative Dermatology, 2019, 139, 964-968.	0.3	48
40	Aggravation of mild axillary hidradenitis suppurativa by microwave ablation: Results of a randomized intrapatientâ€“controlled trial. Journal of the American Academy of Dermatology, 2019, 80, 777-779.	0.6	13
41	The antiâ€inflammatory potency of biologics targeting tumour necrosis factorâ€Î±, interleukin (<scp>IL</scp>)â€17A,<scp>IL</scp>â€12/23 and<scp>CD</scp>20 in hidradenitis suppurativa: anex vivostudy. British Journal of Dermatology, 2019, 181, 314-323.	1.4	38
42	High prevalence of hidradenitis suppurativa in patients with perianal fistula. International Journal of Colorectal Disease, 2019, 34, 1337-1339.	1.0	11
43	Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. British Journal of Dermatology, 2019, 181, 967-975.	1.4	34
44	Virulent Staphylococcus lugdunensis with limited genetic diversity in hidradenitis suppurativa lesions. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e248-e250.	1.3	5
45	IDDF2019-ABS-0293â€…A microbiome pilot study: the exploration of the gut-skin axis in hidradenitis suppurativa. , 2019, , .		0
46	Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization â€“ systematic review and recommendations from the HS ALLIANCE working group. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 19-31.	1.3	168
47	High prevalence of clinical spondyloarthritis features in patients with hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2019, 80, 551-554.e1.	0.6	11
48	Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 761-765.	1.3	13
49	Highlights of the updated Dutch evidenceâ€based and consensusâ€based guideline on psoriasis 2017. British Journal of Dermatology, 2019, 180, 31-42.	1.4	21
50	Correlation of the refined Hurley classification for hidradenitis suppurativa with patientâ€reported quality of life and objective disease severity assessment. British Journal of Dermatology, 2019, 180, 1214-1220.	1.4	19
51	Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. Journal of the American Academy of Dermatology, 2019, 80, 80-88.	0.6	86
52	Hidradenitis suppurativa treated with wide excision and second intention healing: a meaningful local cure rate after 253 procedures. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 459-462.	1.3	33
53	Poor interrater reliability of hidradenitis suppurativa phenotypes. Journal of the American Academy of Dermatology, 2018, 79, 577-578.	0.6	18
54	Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II. British Journal of Dermatology, 2018, 178, 715-721.	1.4	33

#	Article	IF	Citations
55	Novel cytokine and chemokine markers of hidradenitis suppurativa reflect chronic inflammation and itch. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 74, 631-634.	2.7	22
56	Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model. Frontiers in Immunology, 2018, 9, 2965.	2.2	147
57	Comprehensive, Multimodal Characterization of an Imiquimodâ€Induced Human Skin Inflammation Model for Drug Development. Clinical and Translational Science, 2018, 11, 607-615.	1.5	12
58	Laser hair removal alters the disease course in mild hidradenitis suppurativa. JDDG - Journal of the German Society of Dermatology, 2018, 16, 901-903.	0.4	12
59	Laserâ€Haarentfernung verÃndert den Krankheitsverlauf bei leichter Hidradenitis suppurativa. JDDG - Journal of the German Society of Dermatology, 2018, 16, 901-903.	0.4	5
60	Complement Activation in Inflammatory Skin Diseases. Frontiers in Immunology, 2018, 9, 639.	2.2	76
61	Hurley III Hidradenitis Suppurativa Has an Aggressive Disease Course. Dermatology, 2018, 234, 232-233.	0.9	15
62	Treatment of port wine stains using Pulsed Dye Laser, Erbium YAG Laser, and topical rapamycin (sirolimus)â€"A randomized controlled trial. Lasers in Surgery and Medicine, 2017, 49, 104-109.	1.1	33
63	Nonâ€invasive anaesthetic methods for dermatological laser procedures: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1096-1110.	1.3	11
64	Surgical Denervation in the Imiquimod-Induced Psoriasiform Mouse Model. Methods in Molecular Biology, 2017, 1559, 75-81.	0.4	6
65	Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study. American Journal of Clinical Dermatology, 2017, 18, 687-695.	3.3	51
66	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet, The, 2017, 389, 2287-2303.	6.3	884
67	Menses and pregnancy affect symptoms in hidradenitis suppurativa: A cross-sectional study. Journal of the American Academy of Dermatology, 2017, 76, 155-156.	0.6	62
68	Sequence variants in hidradenitis suppurativa: in search of the pathogenic mechanisms. British Journal of Dermatology, 2017, 177, 895-896.	1.4	0
69	Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment. Therapeutic Drug Monitoring, 2017, 39, 333-338.	1.0	6
70	Phototherapy of Psoriasis, a Chronic Inflammatory Skin Disease. Advances in Experimental Medicine and Biology, 2017, 996, 287-294.	0.8	22
71	Development and validation of the International Hidradenitis Suppurativa Severity Score System () Tj ETQq1 1 0.784314 rgBT /Overlo Dermatology, 2017, 177, 1401-1409.	1.4	301
72	Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. British Journal of Dermatology, 2017, 177, 1495-1502.	1.4	48

#	Article	IF	Citations
73	Inflammatory bowel disease is associated with hidradenitis suppurativa: Results from a multicenter cross-sectional study. Journal of the American Academy of Dermatology, 2017, 76, 49-53.	0.6	86
74	Comparison of lidocaine/tetracaine cream and lidocaine/prilocaine cream for local anaesthesia during laser treatment of acne keloidalis nuchae and tattoo removal: results of two randomized controlled trials. British Journal of Dermatology, 2017, 176, 81-86.	1.4	8
75	Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study. British Journal of Dermatology, 2017, 176, 1042-1047.	1.4	89
76	Lentigo maligna â€“ anatomic location as a potential risk factor for recurrences after nonâ€surgical treatment. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 450-454.	1.3	8
77	Hidradenitis suppurativa is not associated with the metabolic syndrome based on body type: A crossâ€sectional study. Journal of Dermatology, 2017, 44, 154-159.	0.6	8
78	IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. Clinical Immunology, 2017, 174, 63-72.	1.4	74
79	Accelerated wound healing after wide excisions in Hidradenitis Suppurativa using autologous splitâ€thickness skin grafting and plateletâ€rich plasma. International Wound Journal, 2017, 14, 583-586.	1.3	4
80	Hurley Staging Refined: A Proposal by the Dutch Hidradenitis Suppurativa Expert Group. Acta Dermato-Venereologica, 2017, 97, 412-413.	0.6	54
81	Normal Skin Microbiota is Altered in Pre-clinical Hidradenitis Suppurativa. Acta Dermato-Venereologica, 2017, 97, 208-213.	0.6	76
82	Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility Study. Therapeutic Drug Monitoring, 2017, 39, 379-386.	1.0	14
83	Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision. British Journal of Dermatology, 2016, 174, 588-593.	1.4	47
84	MCPIP1 RNase Is Aberrantly Distributed inÂPsoriatic Epidermis and Rapidly InducedÂbyÂIL-17A. Journal of Investigative Dermatology, 2016, 136, 1599-1607.	0.3	38
85	Leukocyte Profile in Peripheral Blood and Neutrophil-Lymphocyte Ratio in Hidradenitis Suppurativa: A Comparative Cross-Sectional Study of 462 Cases. Dermatology, 2016, 232, 511-519.	0.9	27
86	Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study. Dermatology, 2016, 232, 407-414.	0.9	13
87	Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series. Journal of the American Academy of Dermatology, 2016, 75, 1151-1155.	0.6	77
88	Hidradenitis suppurativa (HS) is associated with low socioeconomic status (SES): A cross-sectional reference study. Journal of the American Academy of Dermatology, 2016, 75, 755-759.e1.	0.6	56
89	Allergic contact dermatitis caused by topical sirolimus used as an adjuvant for laser treatment of port wine stains. Contact Dermatitis, 2016, 75, 184-185.	0.8	7
90	The Association between Hidradenitis Suppurativa and Crohnâ€™s Disease: in Search of theÂMissing Pathogenic Link. Journal of Investigative Dermatology, 2016, 136, 1747-1748.	0.3	27

#	Article	IF	Citations
91	Hidradenitis suppurativa: development of outcome measure instruments. British Journal of Dermatology, 2016, 175, 242-242.	1.4	0
92	Injection site reactions after subcutaneous oligonucleotide therapy. British Journal of Clinical Pharmacology, 2016, 82, 340-351.	1.1	33
93	Azathioprine lacks efficacy in hidradenitis suppurativa: a retrospective study of nine patients. British Journal of Dermatology, 2016, 174, 639-641.	1.4	14
94	A two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod: excellent cosmesis, but frequent recurrences on the nose. British Journal of Dermatology, 2016, 174, 1134-1136.	1.4	11
95	Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations. Therapeutic Drug Monitoring, 2016, 38, 432-438.	1.0	26
96	Severe fatigue based on anaemia in patients with hidradenitis suppurativa: report of two cases and a review of the literature. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 174-175.	1.3	11
97	Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Reviews in Endocrine and Metabolic Disorders, 2016, 17, 343-351.	2.6	174
98	Inflammatory Mechanisms in Hidradenitis Suppurativa. Dermatologic Clinics, 2016, 34, 51-58.	1.0	61
99	Laser Treatment and Its Implications for Photodamaged Skin and Actinic Keratosis. Current Problems in Dermatology, 2015, 46, 129-135.	0.8	11
100	Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study. British Journal of Dermatology, 2015, 173, 1536-1539.	1.4	7
101	Cytokine analysis in hidradenitis suppurativa supports therapeutic approaches. British Journal of Dermatology, 2015, 173, 1361-1361.	1.4	2
102	Hidradenitis suppurativa: a pilot study to determine the capability of patients to self-assess their Hurley stage. British Journal of Dermatology, 2015, 172, 1418-1419.	1.4	10
103	Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. Journal of the American Academy of Dermatology, 2015, 72, 485-488.	0.6	88
104	European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 619-644.	1.3	802
105	Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation. Dermatology, 2015, 231, 184-190.	0.9	257
106	IL-4 Downregulates IL-1Î² and IL-6 and Induces GATA3 in Psoriatic Epidermal Cells: Route of Action of a Th2 Cytokine. Journal of Immunology, 2015, 195, 1744-1752.	0.4	43
107	The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting. British Journal of Dermatology, 2015, 173, 855-857.	1.4	35
108	Allogeneic Mature Human Dendritic Cells Generate Superior Alloreactive Regulatory T Cells in the Presence of IL-15. Journal of Immunology, 2015, 194, 5282-5293.	0.4	12

#	Article	IF	Citations
109	Pathophysiology of hidradenitis suppurativa: An update. Journal of the American Academy of Dermatology, 2015, 73, S8-S11.	0.6	186
110	Combining biologics with methotrexate in psoriasis: a systematic review. British Journal of Dermatology, 2015, 172, 1676-1680.	1.4	10
111	Phototherapy and Photochemotherapy for Psoriasis. Dermatologic Clinics, 2015, 33, 79-89.	1.0	48
112	Fumarates, a new treatment option for therapy-resistant hidradenitis suppurativa: a prospective open-label pilot study. British Journal of Dermatology, 2015, 172, 828-829.	1.4	9
113	The prevalence of hidradenitis suppurativa in 1093 patients with inflammatory bowel disease. British Journal of Dermatology, 2014, 171, 673-675.	1.4	74
114	Epidemiology of Hidradenitis Suppurativa: Prevalence, Pathogenesis, and Factors Associated with the Development of HS. Current Dermatology Reports, 2014, 3, 54-60.	1.1	14
115	Risk factors, clinical course and longâ€term prognosis in hidradenitis suppurativa: a crossâ€sectional study. British Journal of Dermatology, 2014, 171, 819-824.	1.4	151
116	Hidradenitis suppurativa: A retrospective study ofÂ846ÂDutch patients to identify factors associatedÂwithÂdisease severity. Journal of the American Academy of Dermatology, 2014, 71, 460-467.	0.6	185
117	Langerin ^{neg} conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10723-10728.	3.3	158
118	Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response. British Journal of Dermatology, 2013, 168, 990-998.	1.4	11
119	Caspase-14-Deficient Mice Are More Prone to the Development of Parakeratosis. Journal of Investigative Dermatology, 2013, 133, 742-750.	0.3	35
120	A novel two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod. British Journal of Dermatology, 2013, 168, 1362-1364.	1.4	15
121	Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. British Journal of Dermatology, 2013, 168, 926-927.	1.4	4
122	Non-ablative fractional resurfacing in combination with topical tretinoin cream as a field treatment modality for multiple actinic keratosis: a pilot study and a review of other field treatment modalities. Journal of Dermatological Treatment, 2013, 24, 227-231.	1.1	17
123	Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa. Annals of Internal Medicine, 2012, 157, 846.	2.0	349
124	Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Experimental Dermatology, 2012, 21, 735-739.	1.4	167
125	Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions. British Journal of Dermatology, 2012, 166, 98-106.	1.4	127
126	Adalimumab (antitumour necrosis factor-Î±) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. British Journal of Dermatology, 2012, 166, 298-305.	1.4	113

#	Article	IF	Citations
127	Is mechanical stress an important pathogenic factor in hidradenitis suppurativa?. Experimental Dermatology, 2012, 21, 176-177.	1.4	39
128	Genome-Wide Expression Profiling of Five Mouse Models Identifies Similarities and Differences with Human Psoriasis. PLoS ONE, 2011, 6, e18266.	1.1	160
129	GATA3 Expression Is Decreased in Psoriasis and during Epidermal Regeneration; Induction by Narrow-Band UVB and IL-4. PLoS ONE, 2011, 6, e19806.	1.1	44
130	Narrowband ultraviolet B inhibits innate cytosolic double-stranded RNA receptors in psoriatic skin and keratinocytes. British Journal of Dermatology, 2011, 164, 838-847.	1.4	15
131	Elevated levels of tumour necrosis factor (TNF)-Î±, interleukin (IL)-1Î² and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-Î± and IL-1Î². British Journal of Dermatology, 2011, 164, 1292-1298.	1.4	394
132	Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. European Journal of Pharmacology, 2011, 672, 1-8.	1.7	100
133	Effective Treatment of Psoriasis with Narrow-Band UVB Phototherapy Is Linked to Suppression of the IFN and Th17 Pathways. Journal of Investigative Dermatology, 2011, 131, 1547-1558.	0.3	129
134	Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. British Journal of Dermatology, 2010, 162, 195-197.	1.4	124
135	Deroofing: A tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. Journal of the American Academy of Dermatology, 2010, 63, 475-480.	0.6	167
136	The International Psoriasis Council Presents Top 2009 Research Articles. Psoriasis Forum, 2009, 15a, 24-32.	0.1	0
137	The Effect of Combined Treatment with Oral Clindamycin and Oral Rifampicin in Patients with Hidradenitis Suppurativa. Dermatology, 2009, 219, 143-147.	0.9	188
138	Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis. Journal of Immunology, 2009, 182, 5836-5845.	0.4	1,636
139	IFN-Î± Enhances Poly-IC Responses in Human Keratinocytes by Inducing Expression of Cytosolic Innate RNA Receptors: Relevance for Psoriasis. Journal of Investigative Dermatology, 2008, 128, 932-938.	0.3	67
140	In Psoriasis Lesional Skin the Type I Interferon Signaling Pathway Is Activated, Whereas Interferon-Î± Sensitivity Is Unaltered. Journal of Investigative Dermatology, 2004, 122, 51-60.	0.3	113
141	Psoriatic lesional skin exhibits an aberrant expression pattern of interferon regulatory factor-2 (IRF-2). Journal of Pathology, 2003, 199, 107-114.	2.1	25
142	Interferon-?-induced ICAM-1 and CD40 expression, complete lack of HLA-DR and CD80 (B7.1), and inconsistent HLA-ABC expression in basal cell carcinoma: a possible role for interleukin-10?. , 1999, 187, 351-357.		38
143	IL-1? and IFN-? induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN-? up-regulates the expression of keratin 17 and keratinocyte transglutaminase via endogenous IL-1 production. , 1999, 187, 358-364.		53
144	Expression of interferon-gamma receptors and interferon-gamma-induced up-regulation of intercellular adhesion molecule-1 in basal cell carcinoma; decreased expression of IFN-Î³R and shedding of ICAM-1 as a means to escape immune surveillance. , 1998, 184, 169-176.		36

#	Article	IF	Citations
145	Expression of interferon-gamma receptors and interferon-gamma-induced up-regulation of intercellular adhesion molecule-1 in basal cell carcinoma; decreased expression of IFN-Î³R and shedding of ICAM-1 as a means to escape immune surveillance. , 1998, 184, 169.		1
146	Adhesion molecules and IL-1 costimulate T lymphocytes in the autologous MECLR in psoriasis. Archives of Dermatological Research, 1996, 288, 68-73.	1.1	8
147	Enhanced production of biologically active interleukin-1Î± and interleukin-1Î² by psoriatic epidermal cellsex vivo: evidence of increased cytosolic interleukin-1Î² levels and facilitated interleukin-1 release. European Journal of Immunology, 1995, 25, 1624-1630.	1.6	60
148	The Autologous Mixed Epidermal Cellâ€“T Lymphocyte Reaction Is Elevated in Psoriasis: A Crucial Role for Epidermal HLA-DR+/CD1a- Antigen-Presenting Cells. Journal of Investigative Dermatology, 1990, 96, 880-887.	0.3	32